These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12941314)

  • 1. Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.
    Fraley ME; Arrington KL; Hambaugh SR; Hoffman WF; Cunningham AM; Young MB; Hungate RW; Tebben AJ; Rutledge RZ; Kendall RL; Huckle WR; McFall RC; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2003 Sep; 13(18):2973-6. PubMed ID: 12941314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.
    Fraley ME; Rubino RS; Hoffman WF; Hambaugh SR; Arrington KL; Hungate RW; Bilodeau MT; Tebben AJ; Rutledge RZ; Kendall RL; McFall RC; Huckle WR; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2002 Dec; 12(24):3537-41. PubMed ID: 12443771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors.
    Manley PJ; Balitza AE; Bilodeau MT; Coll KE; Hartman GD; McFall RC; Rickert KW; Rodman LD; Thomas KA
    Bioorg Med Chem Lett; 2003 May; 13(10):1673-7. PubMed ID: 12729639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
    Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
    J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.
    Furet P; Bold G; Hofmann F; Manley P; Meyer T; Altmann KH
    Bioorg Med Chem Lett; 2003 Sep; 13(18):2967-71. PubMed ID: 12941313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A concise synthesis of a novel antiangiogenic tyrosine kinase inhibitor.
    Payack JF; Vazquez E; Matty L; Kress MH; McNamara J
    J Org Chem; 2005 Jan; 70(1):175-8. PubMed ID: 15624920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
    Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
    J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
    Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
    J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
    Underiner TL; Ruggeri B; Aimone L; Albom M; Angeles T; Chang H; Hudkins RL; Hunter K; Josef K; Robinson C; Weinberg L; Yang S; Zulli A
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2368-72. PubMed ID: 18343109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
    Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
    Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
    Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
    J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
    Gangjee A; Zaware N; Raghavan S; Disch BC; Thorpe JE; Bastian A; Ihnat MA
    Bioorg Med Chem; 2013 Apr; 21(7):1857-64. PubMed ID: 23434139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists.
    Simeone JP; Bugianesi RL; Ponpipom MM; Yang YT; Lo JL; Yudkovitz JB; Cui J; Mount GR; Ren RN; Creighton M; Mao AH; Vincent SH; Cheng K; Goulet MT
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3329-32. PubMed ID: 12392744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
    Hudkins RL; Becknell NC; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Albom MS; Chang H; Miknyoczki SJ; Hunter K; Jones-Bolin S; Zhao H; Bacon ER; Mallamo JP; Ator MA; Ruggeri BA
    J Med Chem; 2012 Jan; 55(2):903-13. PubMed ID: 22148921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
    Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
    J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
    Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
    J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
    McDermott LA; Simcox M; Higgins B; Nevins T; Kolinsky K; Smith M; Yang H; Li JK; Chen Y; Ke J; Mallalieu N; Egan T; Kolis S; Railkar A; Gerber L; Luk KC
    Bioorg Med Chem; 2005 Aug; 13(16):4835-41. PubMed ID: 15953730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.